Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 8 member A1 antisense RNA 1 (SLC8A1-AS1)
- Target
- SLC8A1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
SLC8A1 antisense RNA 1 (SLC8A1-AS1) is a long non-coding antisense RNA transcribed from the antisense strand of the *SLC8A1* gene region. It functions primarily in the regulation of gene expression and has diverse roles in different tissues, including the heart and multiple types of cancer. In acute myocardial infarction, SLC8A1-AS1 is downregulated, which leads to the activation of protective pathways such as cGMP-PKG and mitigation of myocardial injury by antagonizing pro-inflammatory signaling and reducing infarct size. In oncology, differential expression of SLC8A1-AS1 has been linked to disease prognosis and patient stratification, with particular relevance in cervical squamous cell carcinoma, glioma, thyroid carcinoma, and oral squamous cell carcinoma seen in risk predictive modeling and biomarker studies. SLC8A1-AS1 exerts its regulatory effects through involvement in competing endogenous RNA networks, affecting the expression and activity of protein-coding genes such as SLC8A1. SLC8A1-AS1 is not considered a direct therapeutic target for drugs, but its expression is of interest as a potential prognostic biomarker.
- Other names
- SLC8A1-AS1NONHSAG027549.2HSALNG0014381
02
Mechanism of action
Not applicable (SLC8A1-AS1 is not a direct drug target)
03
Biological functions
Regulation of gene expression, especially at transcriptional and post-transcriptional levels (as a signal, decoy, guide, or scaffold molecule)Modulation of SLC8A1 (a sodium/calcium exchanger) expression and activityParticipation in the cGMP-PKG signaling pathway and reduction of pro-inflammatory factor release
04
Disease associations
Cardiovascular disease (protective role in acute myocardial infarction, limits myocardial injury)Cancer (expression profiles associated with risk and prognosis in glioma, thyroid carcinoma, oral squamous cell carcinoma, cervical squamous cell carcinoma)
05
Safety considerations
No specific safety concerns or therapeutic challenges noted, as SLC8A1-AS1 itself is not a direct drug target
06
Biomarkers
SLC8A1-AS1 expression levels have been proposed as biomarkers for risk stratification and prognosis in cervical squamous cell carcinoma and other cancers
Beyond the preview
Go deeper on Solute carrier family 8 member A1 antisense RNA 1 (SLC8A1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 8 member A1 antisense RNA 1 (SLC8A1-AS1).